Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Study Number: 

NCG 260614

Phase: 
2/3
Trial categories: 
Lung
Immunotherapy
Checkpoint blockade
Antibody therapy
Principal Investigator: